Clinical Study
Utilization of Preventive Measures for Glucocorticoid-Induced Osteoporosis among Veterans with Inflammatory Bowel Disease
Table 1
Baseline characteristics.
| | Variable | |
| | Gender (male/female) | 61/2 | | Race (Caucasian/African American) | 57/4 | | Mean age at steroid initiation ± SD (years) | 55.0 ± 13.9 | | >age 50 years (%) | 22 | | Type of IBD (Crohn's disease/ulcerative colitis) | 27/36 | | Median IBD duration at steroid initiation (IQR) (years) | 2.0 (1–8) | | Number of steroid courses | 86 | | Prednisone | 69 | | Budesonide | 17 | | Median daily prednisone dose (IQR) (mg) | 15 (9–25) | | Median course duration (IQR) (months) | 6 (4–19) | | Courses by prescribing providers (%) | | | GI | 38 (44.2) | | Rheumatology | 10 (11.6) | | Primary care | 18 (20.9) | | ER/inpatient service | 4 (4.6) | | Unspecified | 16 (18.6) | | Albumin < 3.5 g/dL (%) | 52 (60.4) | | BMI < 21 kg/m2 (%) | 14 (16.3) | | Calcium (%) | 40 (46.5) | | Vitamin D (%) | 39 (45.3) | | Bisphosphonates (%) | 23 (26.7) | | Any treatment (%) | 49 (56.9) | | BMD scans | 26 | | Osteopenia | 11 | | Osteoporosis | 1 |
|
|
